BioXcel Therapeutics missed analyst expectations for its latest quarterly financial results, posting an earnings per share deficit that widened beyond consensus forecasts by $0.07.
In addition to the bottom-line miss, the company's total revenue for the period came in below average Wall Street estimates. Detailed financial figures, including specific revenue totals and net income metrics, were not immediately expanded upon in the initial reporting.
